.svg){kind=small}
We are pleased to announce that our abstract has been selected for an oral presentation at APASL 2024. The Asia-Pacific Association for the Study of Liver (APASL) Congress is an important event in the field of hepatology, bringing together experts from around the globe to discuss the latest advancements, research findings, and clinical insights.
Our presentation promises to contribute valuable insights to the conference program. We are honoured to have this platform to share our research and engage with fellow professionals in the field.
To find out more: https://www.apasl2024kyoto.org/
-min.jpg)
.jpg)
Latest news
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read moreA first of a kind trial in the fight against malaria
June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read moreEvents
AHA Hypertension Scientific Sessions 2024
5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
